Polymers for Solubility Enhancement Will Drive the Oral Solid Dosage Forms Market
Poor solubility has been a major challenge in the formulation development for oral solid dosage form (OSDF) pharmaceuticals, a preferred route for pharmaceutical consumption. Various methods have been researched to improve solubility of poorly soluble APIs and among these the use of polymers for solubility enhancement in solid dispersions is among the most popular.
Identifying the importance of the trend and to fulfil inadequately assessed market for polymers for solubility enhancement, global consulting and research firm Kline & Company is announcing the undertaking of a comprehensive study on Polymers for Solubility Enhancement in Pharmaceutical Oral Solid Dosage Forms: Global Market Analysis and Opportunities. The study will cover current and forecast demand by major products, supplier sales, and technical and market trends, as well as market opportunities and challenges for manufacturers of these polymers worldwide.
Oral administration is a natural means of consumption and is best for chronic drug therapy. In addition, the manufacturing of OSDF can be an advantage compared to other dosage forms; positively impacting the price of pharmaceutical products.
Nikola Matic, Industry Manager at Kline's Chemicals & Materials practice, states: “After having pushed in the direction of OSDFs for many years, the pharmaceutical industry now faces a dilemma stemming from the poor solubility of an increasing number of new drugs. Furthermore, of about 80–90% of products in the R&D pipeline are reported to be poorly soluble in water. As a result, this triggers low oral bioavailability and could in turn jeopardize the development of new drugs.”
Solubility is growing in importance and those who are able to capitalize on the potential that these enhancers bring to the table will see its inherent value. “Solubility enhancement is becoming a must for pharmaceutical companies and an area representing vast growth potential for chemical suppliers since tomorrow’s block-busters will most likely make use of one of the possible technologies to increase dissolution rate,” adds Matic.
This is a complex topic and today’s reality can quickly evolve into something different tomorrow as the industry experiences trends and innovations that influence its course. Kline’s Polymers for Solubility Enhancement in Pharmaceutical Oral Solid Dosage Forms: Global Market Analysis and Opportunities report will introduce all available technology and present their advantages and/or constraints and will focus on the polymers available for solubility enhancement through solid dispersion. The report will provide insights into the global market and regional specificities for solubility enhancement and provide a comprehensive overview of the markets’ present undertakings, and, most importantly, shed light on what lies ahead in the unknown future.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance